When will ruxolitinib/ruxolitinib cream be available for sale in China?

Ruxolitinib is a new type of topical targeted drug that belongs to the JAK (Janus kinase) inhibitor class. It blocks the JAK-STAT signaling pathway and reduces the release of inflammatory cytokines, thereby effectively alleviating skin inflammation and itching symptoms. Unlike oral JAK inhibitors, topical ruxolitinib cream has lower systemic absorption, so there is less risk of systemic side effects, higher safety, and is suitable for long-term management of chronic skin diseases.

The drug has been approved overseas for the treatment of mild to moderate atopic dermatitis (AD) and vitiligo. In patients with atopic dermatitis, ruxolitinib cream can quickly improve rashes, reduce itching, and maintain long-term remission in some cases. In patients with vitiligo, ruxolitinib cream can help the pigment gradually replenish depigmented areas by regulating the immune inflammatory response and promoting the recovery of melanocytes, especially on the face and other parts. The effect is more obvious.

It is worth noting that when using ruxolitinib cream, it is generally recommended to be applied externally twice a day. The effect can be seen for several weeks to several months. The specific course of treatment needs to be adjusted according to the patient's condition and skin reaction. Because the drug's mechanism of action targets a key link in immune inflammation, it may lead to longer-lasting improvements in patients with relapsing or refractory skin inflammation.

At present, ruxolitinib cream has not yet been officially launched for sale in mainland China. The reasons may include the approval cycle, market access assessment and corporate business strategies. Therefore, if domestic patients need medicines, they usually need to obtain them through cross-border drug purchase, purchasing agents from international medical institutions and other channels. Although this method increases the difficulty and cost of acquisition to a certain extent, it also provides a feasible solution for patients with urgent needs.

Reference: https://www.opzelura.com/